MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostics.
Chief Executive Officer Michael McGarrity said the company’s growth strategy has helped transform MDxHealth into a urology-focused precision diagnostics business, with revenue increasing from $11 million in 2019 to $108 million in 2025. However, he said reimbursement uncertainty around Resolve made the business line unsustainable.
